I am a Healthcare Professional

These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.

Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.

Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.

Reject

ISDS 2025 Sanofi | Regeneron | Nov 12, 2025 - Nov 15, 2025

Immunology

Sanofi is committed to advancing the science of immunology through our research and development of innovative therapies for patients with chronic, difficult-to-treat, inflammatory diseases.

Available rooms
1 of 1

  • Atopic Dermatitis

    Atopic dermatitis is a chronic, predominantly type 2 inflammatory disease characterized by intense itch, skin lesions, and increased risk of infections, barrier dysfunction, and poor quality of life.

  • Chronic spontaneous urticaria

    Chronic spontaneous urticaria (CSU) is a systemic, immune-mediated disease characterized by the spontaneous appearance of wheals and/or angioedema leading to debilitating symptoms (e.g., itching and/or burning sensation). Despite a lack of known triggers, CSU can recur for 6 weeks or more resulting in substantial physical, mental, emotional, and socio-economic effects on patients’ quality of life.